Atara Biotherapeutics Inc (NASDAQ:ATRA) shot up 6.9% during mid-day trading on Tuesday . The company traded as high as $43.80 and last traded at $43.50. 1,130,800 shares traded hands during trading, an increase of 56% from the average session volume of 726,445 shares. The stock had previously closed at $40.70.

A number of research firms have recently issued reports on ATRA. Zacks Investment Research raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, June 6th. Citigroup lowered their price target on shares of Atara Biotherapeutics from $25.00 to $23.00 and set a “sell” rating on the stock in a research report on Monday, June 11th. BidaskClub cut shares of Atara Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 8th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $45.00 price target on shares of Atara Biotherapeutics in a research report on Friday, August 3rd. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Atara Biotherapeutics currently has an average rating of “Hold” and an average price target of $43.17.

The stock has a market cap of $1.81 billion, a price-to-earnings ratio of -10.88 and a beta of 2.54.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.17). equities analysts forecast that Atara Biotherapeutics Inc will post -4.58 EPS for the current year.

In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 58,400 shares of the company’s stock in a transaction dated Tuesday, July 10th. The shares were sold at an average price of $40.00, for a total value of $2,336,000.00. Following the transaction, the chief executive officer now owns 812,613 shares of the company’s stock, valued at $32,504,520. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Christopher Haqq sold 775 shares of the company’s stock in a transaction dated Wednesday, August 15th. The shares were sold at an average price of $37.54, for a total transaction of $29,093.50. Following the completion of the transaction, the executive vice president now directly owns 331,355 shares in the company, valued at approximately $12,439,066.70. The disclosure for this sale can be found here. In the last three months, insiders have sold 142,675 shares of company stock worth $5,593,522. Corporate insiders own 10.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of ATRA. SG Americas Securities LLC acquired a new position in Atara Biotherapeutics in the first quarter valued at about $107,000. Great West Life Assurance Co. Can lifted its position in Atara Biotherapeutics by 100.1% in the second quarter. Great West Life Assurance Co. Can now owns 3,309 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 1,655 shares during the last quarter. Bank of Montreal Can acquired a new position in Atara Biotherapeutics in the second quarter valued at about $180,000. Highland Private Wealth Management acquired a new position in Atara Biotherapeutics in the second quarter valued at about $202,000. Finally, Principal Financial Group Inc. acquired a new position in Atara Biotherapeutics in the first quarter valued at about $214,000.

About Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

See Also: Beta

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.